DNA Repair-Based Gene Expression Signature and Distinct Molecular Subtypes for Prediction of Clinical Outcomes in Lung Adenocarcinoma

Bin Hu,Di Liu,Yinqiang Liu,Zhixi Li
DOI: https://doi.org/10.3389/fmed.2020.615981
IF: 3.9
2020-11-27
Frontiers in Medicine
Abstract:Objective: To conduct a robust prognostic gene expression signature and characterize molecular subtypes with distinct clinical characteristics for lung adenocarcinoma (LUAD). Methods: Based on DNA repair genes from the GSEA database, a prognostic signature was conducted in the TCGA-LUAD training set via univariate and multivariate cox regression analysis. Its prediction power was validated by overall survival analysis, relative operating characteristic (ROC) curves and stratification analysis in the GSE72094 verification set. Involved pathways in the high- and low-risk groups were analyzed by GSEA. A nomogram was built based on the signature and clinical features and its performance was assessed by calibration plots. LUAD samples were clustered via the ConsensusClusterPlus package. The differences in clinical outcomes, single nucleotide polymorphism (SNP) and sensitivity to chemotherapy drugs between molecular subtypes were analyzed. Results: A 13-DNA repair gene-signature was constructed for LUAD prognosis. Following validation, it can robustly and independently predict patients' clinical outcomes. The GSEA results exhibited the differences in pathways between high- and low- risk groups. A nomogram combining the signature and stage could accurately predict 1-, 3-, and 5-year survival probability. Two distinct molecular subtypes were characterized based on DNA repair genes. Patients in the Cluster 2 exhibited a worse prognosis and were more sensitive to common chemotherapy than those in the Cluster 1. Conclusion: This study proposed a 13-DNA repair gene-signature as a prognostic factor for LUAD patients, which can independently predict clinical outcomes by complement of the stage. Moreover, we characterized two LUAD subtypes with distinct clinical outcomes, somatic gene mutations, and drug sensitivity in cancer based on DNA repair genes.
medicine, general & internal
What problem does this paper attempt to address?
The problems that this paper attempts to solve are: 1. **Construct a robust gene - expression signature**: Based on DNA - repair - related genes, construct a gene - expression signature that can predict the clinical prognosis of patients with lung adenocarcinoma (LUAD). 2. **Characterize molecular subtypes**: According to the expression profiles of DNA - repair - related genes, characterize LUAD molecular subtypes with different clinical features. 3. **Improve clinical application value**: By combining the gene - expression signature and clinical stage, develop a nomogram that can accurately predict the 1 - year, 3 - year, and 5 - year survival probabilities of LUAD patients, thereby providing more precise guidance for clinical treatment. ### Specific problem description - **Background**: Lung adenocarcinoma (LUAD) is a subtype of non - small - cell lung cancer (NSCLC), accounting for 50% of all NSCLC cases. Although surgical resection can be carried out in the early stage, the clinical prognosis of LUAD patients is still poor, with a high risk of recurrence. In addition, the high chemoresistance leads to recurrence and treatment failure, ultimately reducing the patient's survival time. - **Research objective**: By analyzing the expression profiles of DNA - repair - related genes, construct a gene - expression signature that can independently predict the clinical prognosis of LUAD patients, and characterize two molecular subtypes with different clinical features. - **Methods**: - Screen 150 DNA - repair - related genes from the GSEA database. - Use univariate and multivariate Cox regression analyses to screen out 13 genes related to LUAD prognosis from these genes and construct a risk - score model. - Verify the predictive performance of this model through survival analysis, ROC curves, and stratified analysis. - Use the Consensus Clustering method to divide LUAD samples into two molecular subtypes and analyze their clinical features, mutation status, and chemotherapeutic drug sensitivity. - **Results**: - Constructed a prognostic signature consisting of 13 DNA - repair - related genes, which can independently predict the clinical prognosis of LUAD patients. - Characterized two LUAD molecular subtypes with different clinical features. Among them, patients in Cluster 2 have a poorer prognosis and are more sensitive to common chemotherapeutic drugs. - Developed a nomogram that combines risk scores and stages and can accurately predict the 1 - year, 3 - year, and 5 - year survival probabilities. ### Conclusion This study proposed a prognostic signature based on 13 DNA - repair - related genes, which can independently predict the clinical prognosis of LUAD patients and characterized two molecular subtypes with different clinical features, providing new ideas for personalized treatment of LUAD patients.